EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Impact of early discontinuation of adjuvant endocrine therapy on survival in breast cancer: A target trial emulation

Hanxiao Zuo, Edward Vaihenberg, Armaan Singh, Gurniwaz Bal, Gilbert Bigras, David Fenton, Karen King, Yan Yuan, Kurian Joseph

European Journal of Cancer · 2025-09 · 227 · 115665

DOI: 10.1016/j.ejca.2025.115665 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Cancer, 2025-09. Verfasst von Hanxiao Zuo und 8 weiteren Autor:innen. Beteiligte Einrichtung: School of Public Health, University of Alberta, Edmonton, AB, Canada. Hauptthemen laut MEDLINE: Breast Neoplasms, Antineoplastic Agents, Hormonal. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: China Scholarship Council, Natural Sciences and Engineering Research Council of Canada.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Early discontinuation of adjuvant endocrine therapy (AET) among patients with estrogen receptor-positive (ER+) breast cancer (BC) is common. Observational studies reported inconsistent effects of early AET discontinuation on survival outcomes, with limited causal evidence. METHODS: We identified women aged 50-80, diagnosed with first primary ER+ BC between 2010-2015, who underwent surgery in Alberta, Canada. The average effect of early AET discontinuation on survival outcomes was estimated by emulating a target trial. Risk factors for early AET discontinuation were evaluated. RESULTS: Of 6823 eligible patients, 21.8 % did not receive AET, 27.3 % discontinued AET within early, and 50.9 % adhered to the 5-year AET. Compared to adhering to 5-year AET, early discontinuation increased the hazard of overall death and recurrence, with greater effects in higher tumor stages. Early discontinuation also significantly increased the risk of breast cancer-specific death (HR=3.92, 95 % CI: 2.96-5.20), but no interaction with tumor stage was observed. No significant difference in survival outcomes was observed between patients discontinuing AET at 4-5 years and those completing 5 years. Older age (>70 years) at diagnosis, lower-stage disease, HER2-negative status, and absence of chemotherapy or radiotherapy were associated with early discontinuation. CONCLUSIONS: Over one-third of ER+ BC patients in our cohort discontinued AET early, which was associated with increased risks of recurrence and mortality. The impact of early discontinuation varied by tumor stage, and one-year reduction in AET duration did not appear to compromise effectiveness. Implementing targeted interventions for ER+ patients may help improve adherence and survival outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsAntineoplastic Agents, HormonalHumansFemaleMiddle AgedAgedChemotherapy, AdjuvantAged, 80 and overAlbertaReceptors, EstrogenNeoplasm Recurrence, LocalTime Factors

Stichwörter der Autor:innen

Adjuvant endocrine therapyBreast cancerEarly discontinuationTarget trial emulationTreatment effects

Substanzen

Antineoplastic Agents, HormonalReceptors, Estrogen

Autor:innen und Institutionen

  • School of Public Health, University of Alberta, Edmonton, AB, Canada.
  • Department of Psychology, Queens College, City University of New York, USA.
  • University of Alberta, Edmonton, AB, Canada.
  • Laboratory Medicine & Pathology Department, University of Alberta & Cross Cancer Institute, Edmonton, AB, Canada.
  • Department of Oncology, University of Alberta & Cross Cancer Institute, Edmonton, AB, Canada.
  • Department of Oncology, University of Alberta & Cross Cancer Institute, Edmonton, AB, Canada. Electronic address: kurian.joseph@albertahealthservices.ca.

Förderung

  • China Scholarship Council
  • Natural Sciences and Engineering Research Council of Canada

Zitieren

APA

Zuo, H., Vaihenberg, E., Singh, A., Bal, G., Bigras, G., Fenton, D., King, K., Yuan, Y., & Joseph, K. (2025). Impact of early discontinuation of adjuvant endocrine therapy on survival in breast cancer: A target trial emulation. European Journal of Cancer, 227, 115665. https://doi.org/10.1016/j.ejca.2025.115665

Vancouver

Zuo H, Vaihenberg E, Singh A, Bal G, Bigras G, Fenton D, et al. Impact of early discontinuation of adjuvant endocrine therapy on survival in breast cancer: A target trial emulation. European Journal of Cancer. 2025;227:115665. doi:10.1016/j.ejca.2025.115665

BibTeX
@article{Zuo2025,
  author = {Zuo, Hanxiao and Vaihenberg, Edward and Singh, Armaan and Bal, Gurniwaz and Bigras, Gilbert and Fenton, David and King, Karen and Yuan, Yan and Joseph, Kurian},
  title = {Impact of early discontinuation of adjuvant endocrine therapy on survival in breast cancer: A target trial emulation},
  journal = {European Journal of Cancer},
  year = {2025},
  volume = {227},
  pages = {115665},
  doi = {10.1016/j.ejca.2025.115665}
}
Kostenlos starten →